Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region

BMC Genetics

Afrouz Behboudi¹  Staffan Nilsson²  Sandra Karlsson¹  Emma Samuelson³  Kittichate Visuttijai¹  Anna Linder³  Diego Garcia Dios³  Carola Hedberg Oldfors³ 

[1] Tumor Biology Research Group, School of Bioscience, University of Skövde, Skövde, SE-54128, Sweden;Institute of Mathematical Statistics, Chalmers University of Technology, Gothenburg, SE-41296, Sweden;Department of Medical and Clinical Genetics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SE-40530, Sweden

关键词: Myo1c;    Skip;    Inpp5k;    Hic1;    Tp53;    RNO10q24-q25;    17p13.3;    Endometrial carcinoma;   

Others  :  1219403
DOI  :  10.1186/s12863-015-0238-4

 received in 2015-03-12, accepted in 2015-06-23,  发布年份 2015

【 摘 要 】

Background

Several reports indicate a commonly deleted chromosomal region independent from, and distal to the TP53 locus in a variety of human tumors. In a previous study, we reported a similar finding in a rat tumor model for endometrial carcinoma (EC) and through developing a deletion map, narrowed the candidate region to 700 kb, harboring 19 genes. In the present work real-time qPCR analysis, Western blot, semi-quantitative qPCR, sequencing, promoter methylation analysis, and epigenetic gene expression restoration analyses (5-aza-2´-deoxycytidine and/or trichostatin A treatments) were used to analyze the 19 genes located within the candidate region in a panel of experimental tumors compared to control samples.

Results

Real-time qPCR analysis suggested Hic1 (hypermethylated in cancer 1), Inpp5k (inositol polyphosphate-5-phosphatase K; a.k.a. Skip, skeletal muscle and kidney enriched inositol phosphatase) and Myo1c (myosin 1c) as the best targets for the observed deletions. No mutation in coding sequences of these genes was detected, hence the observed low expression levels suggest a haploinsufficient mode of function for these potential tumor suppressor genes. Both Inpp5k and Myo1c were down regulated at mRNA and/or protein levels, which could be rescued in gene expression restoration assays. This could not be shown for Hic1.

Conclusion

Innp5k and Myo1c were identified as the best targets for the deletions in the region. INPP5K and MYO1C are located adjacent to each other within the reported independent region of tumor suppressor activity located at chromosome arm 17p distal to TP53 in human tumors. There is no earlier report on the potential tumor suppressor activity of INPP5K and MYO1C, however, overlapping roles in phosphoinositide (PI) 3-kinase/Akt signaling, known to be vital for the cell growth and survival, are reported for both. Moreover, there are reports on tumor suppressor activity of other members of the gene families that INPP5K and MYO1C belong to. Functional significance of these two candidate tumor suppressor genes in cancerogenesis pathways remains to be investigated.

【 授权许可】

   
2015 Oldfors et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. Journal of Molecular Medicine-Jmm. 1997; 75:429-439.
• [2]Bova GS, Isaacs WB. Review of allelic loss and gain in prostate cancer. World Journal of Urology. 1996; 14:338-346.
• [3]Kaneko Y, Homma C, Maseki N, Sakurai M, Hata J. Correlation of Chromosome-Abnormalities with Histological and Clinical-Features in Wilms and Other Childhood Renal Tumors. Cancer Research. 1991; 51:5937-5942.
• [4]Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E et al.. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood. 1998; 91:616-622.
• [5]Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nature Reviews Cancer. 2009; 9:95-107.
• [6]Guan XY, Sham JS, Tai LS, Fang Y, Li H, Liang Q. Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma. Cancer genetics and cytogenetics. 2003; 140:45-48.
• [7]Konishi H, Sugiyama M, Mizuno K, Saito H, Yatabe Y, Takahashi T et al.. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer. Oncogene. 2003; 22:1892-1905.
• [8]Roncuzzi L, Brognara I, Baiocchi D, Amadori D, Gasperi-Campani A. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer. Oncology reports. 2005; 14:471-474.
• [9]Sarkar C, Chattopadhyay P, Ralte AM, Mahapatra AK, Sinha S. Loss of heterozygosity of a locus in the chromosomal region 17p13.3 is associated with increased cell proliferation in astrocytic tumors. Cancer Genetics and Cytogenetics. 2003; 144:156-164.
• [10]Nordlander C, Karlsson S, Karlsson A, Sjoling A, Winnes M, Klinga-Levan K et al.. Analysis of chromosome 10 aberrations in rat endometrial cancer-evidence for a tumor suppressor locus distal to Tp53. Int J Cancer. 2007; 120:1472-1481.
• [11]Behboudi A, Levan G, Hedrich HJ, Klinga-Levan K. High-density marker loss of heterozygosity analysis of rat chromosome 10 in endometrial adenocarcinoma. Genes, Chromosomes and Cancer. 2001; 32:330-341.
• [12]Helou K, Walentinsson A, Beckmann B, Johansson A, Hedrich HJ, Szpirer C, Klinga-Levan K, Levan G. Analysis of genetic changes in rat endometrial carcinomas by means of comparative genomic hybridization. Cancer Genet Cytogenet. 2001; 127:118-27.
• [13]Nordlander C, Behboudi A, Levan G, Levan KK. Allelic imbalance on chromosome 10 in rat endometrial adenocarcinomas. Cancer Genet Cytogenet. 2005; 156:158-166.
• [14]Chen L, Nordlander C, Behboudi A, Olsson B, Levan KK. Deriving evolutionary tree models of the oncogenesis of endometrial adenocarcinoma. Int J Cancer. 2007; 120:292-296.
• [15]Behboudi A, Hedrich HJ, Szpirer C, Levan G, Klinga-Levan K. Loss of heterozygosity analysis of rat chromsome 10 in endometrial adenocarcinoma. Rat Genome. 2000; 6:77.
• [16]Hamta A, Adamovic T, Helou K, Levan G. Cytogenetic aberrations in spontaneous endometrial adenocarcinomas in the BDII rat model as revealed by chromosome banding and comparative genome hybridization. Cancer Genetics and Cytogenetics. 2005; 159:123-128.
• [17]Kobashigawa Y, Sakai M, Naito M, Yokochi M, Kumeta H, Makino Y et al.. Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK. Nature Structural & Molecular Biology. 2007; 14:503-510.
• [18]Nishihara H, Tanaka S, Tsuda M, Oikawa S, Maeda M, Shimizu M et al.. Molecular and immunohistochemical analysis of signaling adaptor protein Crk in human cancers. Cancer Letters. 2002; 180:55-61.
• [19]Wang L, Tabu K, Kimura T, Tsuda M, Linghu H, Tanino M et al.. Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. Biochemical and Biophysical Research Communications. 2007; 362:976-981.
• [20]Knudson AG. A two-mutation model for human cancer. Advances in Viral Oncology. 1987; 7:1-7.
• [21]Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W et al.. Regional DNA Hypermethylation at D17s5 Precedes 17p Structural-Changes in the Progression of Renal Tumors. Cancer Research. 1993; 53:2719-2722.
• [22]Morton RA, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB. Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. Journal of Urology. 1996; 156:512-516.
• [23]Astle MV, Seaton G, Davies EM, Fedele CG, Rahman P, Arsala L et al.. Regulation of phosphoinositide signaling by the inositol polyphosphate 5-phosphatases. Iubmb Life. 2006; 58:451-456.
• [24]Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics. 2006; 7:606-619.
• [25]Ijuin T, Takenawa T. SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formation. Molecular and Cellular Biology. 2003; 23:1209-1220.
• [26]Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Journal of Biological Chemistry. 1998; 273:13375-13378.
• [27]Bond LM, Brandstaetter H, Kendrick-Jones J, Buss F. Functional roles for myosin 1c in cellular signaling pathways. Cell Signal. 2013; 25:229-235.
• [28]Brandstaetter H, Kendrick-Jones J, Buss F. Myo1c regulates lipid raft recycling to control cell spreading, migration and Salmonella invasion. J Cell Sci. 2012; 125:1991-2003.
• [29]Oh H, Kim H, Shin B, Lee KH, Yeo MG, Song WK. Interaction of crk with Myosin-1c participates in fibronectin-induced cell spreading. Int J Biol Sci. 2013; 9:778-791.
• [30]Hokanson DE, Ostap EM. Myo1c binds tightly and specifically to phosphatidylinositol 4,5-bisphosphate and inositol 1,4,5-trisphosphate. Proc Natl Acad Sci U S A. 2006; 103:3118-3123.
• [31]Bose A, Guilherme A, Robida SI, Nicoloro SM, Zhou QL, Jiang ZY et al.. Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. Nature. 2002; 420:821-824.
• [32]Holman GD, Sakamoto K. Regulating the Motor for GLUT4 Vesicle Traffic. Cell Metabolism. 2008; 8:344-346.
• [33]Yip MF, Ramm G, Larance M, Hoehn KL, Wagner MC, Guilhaus M et al.. CaMKII-Mediated Phosphorylation of the Myosin Motor Myolc Is Required for Insulin-Stimulated GLUT4 Translocation in Adipocytes. Cell Metabolism. 2008; 8:384-398.
• [34]Nishioka M, Kohno T, Tani M, Yanaihara N, Tomizawa Y, Otsuka A et al.. MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proc Natl Acad Sci U S A. 2002; 99:12269-12274.
• [35]Taki T, Akiyama M, Saito S, Ono R, Taniwaki M, Kato Y et al.. The MYO1F, unconventional myosin type 1 F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22. Oncogene. 2005; 24:5191-5197.
• [36]Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature reviews Cancer. 2009; 9:550-562.
• [37]Deerberg F, Kaspareit J. Endometrial carcinoma in BDII/Han rats: model of a spontaneous hormone-dependent tumor. Journal of the National Cancer Institute. 1987; 78:1245-1251.
• [38]Kaspareit-Rittinghausen J, Deerberg F, Rapp K. Mortality and incidence of spontaneous neoplasms in BDII/Han rats. Zeitschrift für Versuchstierkunde. 1987; 30:209-216.
• [39]Roshani L, Mallon P, Sjostrand E, Wedekind D, Szpirer J, Szpirer C et al.. Genetic analysis of susceptibility to endometrial adenocarcinoma in the BDII rat model. Cancer Genetics and Cytogenetics. 2005; 158:137-141.
• [40]Roshani L, Wedekind D, Szpirer J, Taib Z, Szpirer C, Beckman B et al.. Genetic identification of multiple susceptibility genes involved in the development of endometrial carcinoma in a rat model. International Journal of Cancer. 2001; 94:795-799.
• [41]Samuelson E, Hedberg C, Nilsson S, Behboudi A. Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats. Endocr Relat Cancer. 2009; 16:99-111.
• [42]Caren H, Fransson S, Ejeskar K, Kogner P, Martinsson T. Genetic and epigenetic changes in the common Ip36 deletion in neuroblastoma tumours. British Journal of Cancer. 2007; 97:1416-1424.